| Identification | Back Directory | [Name]
norisoboldine | [CAS]
23599-69-1 | [Synonyms]
norisoboldine
(+)-Laurelliptine
(+)-Norisoboldine
(+)-N-Norisoboldine
(S)-(+)-Laurelliptine
Norisoboldine, 98%, from Lindera aggregata (Sims) Kosterm.
(6aS)-5,6,6a,7-Tetrahydro-2,10-dimethoxy-4H-dibenzo[de,g]quinoline-1,9-diol
4H-Dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (6aS)- | [Molecular Formula]
C18H19NO4 | [MDL Number]
MFCD09953815 | [MOL File]
23599-69-1.mol | [Molecular Weight]
313.35 |
| Chemical Properties | Back Directory | [Melting point ]
89-191℃ | [Boiling point ]
553.0±50.0 °C(Predicted) | [density ]
1.313 | [solubility ]
≥ 31.3mg/mL in DMSO | [form ]
Powder | [pka]
9.58±0.20(Predicted) | [color ]
Brown to khaki |
| Hazard Information | Back Directory | [Uses]
(+)-Norisoboldine is an anti-arthritis alkaloid isolated from radix linderae which has been shown to attenuate osteoclast differentiation and inflammatory bone erosion in aryl hydrocarbon receptor-dependant manner. | [in vivo]
Norisoboldine (10~40 mg/kg; p.o.; 20 days) significantly reduces the severity of joint swelling and erythema during the course of the experiment[1].
Norisoboldine (40 mg/kg; i.g.; 10 days) induces enhancement of CYP1A1 expression and suppresses expressions of Glut1 and HK2 in colons[2]. | Animal Model: | Male ICR mice (18–22 g) | | Dosage: | 10~40 mg/kg | | Administration: | P.o. | | Result: | Significantly reduced the severity of joint swelling and erythema during the course of the experiment.
|
| Animal Model: | Female C57BL/6 mice (18–22 g) | | Dosage: | 40 mg/kg | | Administration: | I.g. | | Result: | Induced enhancement of CYP1A1 expression and suppressed expressions of Glut1 and HK2 in colons.
|
|
|
|